Sanofi
Dupixent
allergic fungal rhinosinusitis
Resolved
133days ago
Phase 3 readout · Feb 24, 2026
What's at stake
Phase 3 trial results for Dupixent in allergic fungal rhinosinusitis are due Feb 24, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“The FDA approval is supported by the LIBERTY-AFRS-AIMS phase 3 study (clinical study identifier: NCT04684524 ), in which 62 adults and children aged 6 years and older with AFRS were randomized to receive an age- and weight-based dose of Dup”